A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors

BACKGROUND. Sorafenib and dacarbazine have low single‐agent response rates in metastatic sarcomas. As angiogenesis inhibitors can enhance the efficacy of chemotherapy, we investigated the combination of sorafenib and dacarbazine in select sarcoma subtypes. MATERIALS AND METHODS. Patients with leiomy...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Oncologist
Asıl Yazarlar: D'Adamo, David R., Dickson, Mark A., Keohan, Mary L., Carvajal, Richard D., Hensley, Martee L., Hirst, Catherine M., Ezeoke, Marietta O., Ahn, Linda, Qin, Li‐Xuan, Antonescu, Cristina R., Lefkowitz, Robert A., Maki, Robert G., Schwartz, Gary K., Tap, William D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: John Wiley & Sons, Inc. 2018
Konular:
Sarcomas
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6656505/
https://ncbi.nlm.nih.gov/pubmed/30126857
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0160
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller